Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.20 14.81% 1.55 1,217,684 13:29:08
Bid Price Offer Price High Price Low Price Open Price
1.50 1.60 1.55 1.35 1.35
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.72 -0.20 -0.14 1
Last Trade Time Trade Type Trade Size Trade Price Currency
14:24:08 O 30,000 1.60 GBX

Physiomics (PYC) Latest News

More Physiomics News
Physiomics Takeover Rumours

Physiomics (PYC) Discussions and Chat

Physiomics Forums and Chat

Date Time Title Posts
30/3/202015:51Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni4,762
23/12/201911:41PHYSIOMICS plc Virtual Tumor platform4,935
30/9/201908:08PYC - Podcast-
07/8/201915:36Physiomics with Charts & News13,716
01/12/201719:18RGP NEXT MULTI BAGGER TODAY 50p4

Add a New Thread

Physiomics (PYC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:24:091.6030,000480.00O
12:30:261.6062,289996.00O
12:29:001.6012,030192.00O
12:26:531.5763,440996.01O
12:14:141.5820,000316.00O
View all Physiomics trades in real-time

Physiomics (PYC) Top Chat Posts

DateSubject
31/3/2020
09:20
Physiomics Daily Update: Physiomics Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 1.35p.
Physiomics Plc has a 4 week average price of 1.35p and a 12 week average price of 1.35p.
The 1 year high share price is 4.40p while the 1 year low share price is currently 1.35p.
There are currently 71,910,394 shares in issue and the average daily traded volume is 1,121,017 shares. The market capitalisation of Physiomics Plc is £1,114,611.11.
11/2/2020
11:03
the stigologist: Computational Biology sector should be on fire today after ETX SP Angel... "e-therapeutics (ETX.L): Board restructuring Share Price: 3.9p; Market Capitalisation: £10.5m * e-therapeutics, a computational drug discovery business, announced board restructuring and a £1.6m placing. * Ali Mortazavi has been appointed Executive Chairman, with the current Non-Executive Chairman, CEO and CFO departing the Company. * The Group also £1.6m placing at 3p/share with the funds to be used for general working capital purposes. The appointment of Mr Mortazavi, who was CEO of Silence Therapeutics (SLN.L), for six years, marks an opportunity to turnaround the business, which was affected last year by the Woodford overhang. The current Group strategy is to strike revenue or cash generating collaborations through its network-driven drug discovery (NDD) and Genome Associated Interaction Networks (GAINs) platforms and has collaborations with big pharma, including Novo Nordisk. Computer-based drug development is an attractive prospect for industry, as it could dramatically reduce risk, cost and time by generating data in silicon rather than in the lab."
23/1/2020
09:44
the stigologist: Obviously they must be expecting share price to improve and understand they are in a land grab phase so it's 'eat or be eaten' ? I would point once again to ETX E-therapeutics Mkt Cap £10m PYC Physiomics Mkt Cap £2m which look crazily undervalued when Private UK Unicorns like Exscientia and BenevolentAI valued at $1000m+ (vs SENS at £60m Mkt with £40m cash) htTps://www.thetimes.co.uk/article/sensyne-health-on-the-acquisition-trail-to-halt-decline-in-share-price-jmfvbcw0q Sensyne Health on the acquisition trail to halt decline in share ... Sensyne Health said that it was “exploring a small number of strategic [mergers and acquisitions] opportunities that have the potential to scale our businessmore quickly to achieve a leadership position in the clinical artificial intelligence market and create value for shareholders”.
24/12/2019
11:27
the stigologist: £100m Market Cap and 150p+ share price on cards if they deliver in AI / ML Artificial Intelligence and Machine Learning applied to biotech and Personalised Medicine hTtps://twitter.com/Stockonomist/status/1209434497894297603?s=20
23/12/2019
11:40
bobdown2: I used to own loads...but zilch now...without reading previous statements I would imagine that next years outlook has been improved substantially and the share price might improve. The last massive rise and now two contracts close together suggest it's could be a good gamble from these levels...I will keep my eyes open for the next Rns statement.
16/7/2019
12:34
herb clark: Will they need to raise cash? If they have landed either of these clients what do you think the share price will rise to?
13/12/2018
10:50
badger60: Institutional OwnershipInstitutions account for 77.04% of PYC's outstanding shares, a significant enough holding to move stock prices if they start buying and selling in large quantities, especially when there are relatively small amounts of shares available on the market to trade. Although PYC has a high institutional ownership, such stock moves, in the short-term, are more commonly linked to a particular type of active institutional investors – hedge funds. In the case of PYC, investors need not worry about such volatility considering active hedge funds don't have a significant stake. However, we should dig deeper into PYC's ownership structure and find out how other key ownership classes can affect its investment profile.Insider OwnershipInsiders form a group of important ownership types as they manage the company's operations and decide the best use of capital. Insider ownership has been linked to better alignment between management and shareholders. Although individuals in PYC hold only a 1.98% stake, it's a good sign for shareholders as the company's executives and directors have their incentives directly linked to the company's performance. In addition to this, it may be interesting to look at insider buying and selling activities. Keep in mind that buying may be sign of upbeat future expectations, but selling doesn't necessarily mean the opposite as the insiders might just be doing it out of their personal financial needs.General Public OwnershipThe general public holds a substantial 20.92% stake in PYC, making it a highly popular stock among retail investors. This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. This is a positive sign for an investor who wants to be involved in key decision-making of the company.Private Company OwnershipAnother group of owners that a potential investor in PYC should consider are private companies, with a stake of 0.028%. While they invest more often due to strategic interests, an investment can also be driven by capital gains through share price appreciation. However, an ownership of this size may be relatively insignificant, meaning that these shareholders may not have the potential to influence PYC's business strategy. Thus, investors not need worry too much about the consequences of these holdings.
10/6/2018
15:31
pwhite73: OBD The current share price does not represent or misrepresent any value. The current share price is where mug punters are buying in order to support the next placing. The value of an AIM company and its share price completely divorced about 5 years ago. When was the last time you heard the term Price Earnings Ratio applied to an AIM stock. It cannot be that PYC was worth 32p per share in December 2017 valuing the company at £19 million and today the placing has valued the same company at just £2.8 million. Where has £16 million of value disappeared to in the space of seven months. You may not know where the share price will be in one years time but I certainly do. It will be back to 1p and this time it will stay there because mug punters are not going to be fooled again (he thinks!!). I have stated before and I'll say so again if it had not been for the November 2017 frenzy I believe PYC would have sought to exit from the AIM.
27/12/2017
11:08
margic: It's a good thing for the PYC share price that eyes have just come off this. As buyers start to return this can move very very quick before the herd arrive and when the herd arrive we spike. Signal to take profit and re-load as the herd exit with their losses and smaller profits. Hope to see this 10p+ before volumes really pick up. Keep watch as PYC can flash bang wallop!
18/12/2017
09:06
the stigologist: Todays VAL Valirx news on VAL201 is also great news for PYC. Expect PYC share price to follow VAL up
17/12/2017
11:28
margic: Great stuff mate and exactly what I was hoping for, you've opened the doors for everyone to take note and find where to search, it's research and posts like that, that can move a stock and why not, there new information to see for investors to start predicting a value and assessing the share price tools to decide if PYC represents value. Centara is a great example, I highly doubt PYC would be taken out for anywhere near that figure based on the past but then again, was it here I read the directors have been ousted? That might change the picture. The bod I remember for years ago were no good to share holders but then again, why would you want long term shareholders when you have a big big play behind closed doors and a shocking share price. Price makes the mouth water now. 11.5p circa £6mil market cap, in a market that can quickly add £50mil valve on anything material that investors can put there eyes on. Even the $32mil take over in 2012 coming out of the burst. More money is spent now and it doesn't take much for a big boy to offer £35-50mil for a small slice, it helps them balance their spending. As I understand it, big pharmacy have a budget quota that must be spent year on year on certain aspects of the business and accumulating businesses, investment partnerships, support and R&D have the highest budgets set in both fiscal cash and time. These budgets. I may be wrong but GSK used to spend like 1bil dollars min a year on failed products before the 80's even. Certainly with now only 57odd mil shares in circulation this is a good time for PYC. I'm sure they can prove the markets cap to £12-15mil and then raising money to boost the line will become comfortable. Unless a take over offer happens out of no where you'd have to expect PYC to place just over 100mil shares, but it's very possible they could secure £10-30mil doing that. Big money for them, not sure they've ever had that at their disposal. As always it will be down to the bod and how soon they want to make their money. Many old money directors have 50-75years for their plays to come good.Is there any key news expected from the faithful? How do you see the BOD moving the company going forward, has anyone meet them or heard them speak? Thanks for the informative stuff stig. I'm only just flirting back in the aim market, I'm a technical trader now with currency's but I do like the aim. It seems now is like 2007-2011 all over again. Rises do seem much bigger. A good start for me has been some of the oldies im familiar with have been squeezed almost to the max and everything is jumping like true penny stocks should.PYC for starters, great news, big share price jump, hype, 57 something mil shares £6mil value, same as always, jumped in with 3mil market cap, can always go £12-15mil outta now where £35-50mil on transformational news, and £100mil + on a well sourced city take over rumour or bid. Bid less likely in normal terms but then again, Takeovers in the Pharma game are normally as good if not better than the tech industry. Disney splashing out £34bil, for essentially parts of a business, imagine what big pharmacy made will pay to wrap a deal up quick. It's not a ramp but I do know if GSK want a business they think a rival will want, they make an offer that won't be matched to conduct a move super quick. If PYC was valued by a proper surveying team at say £65mil (figure I've come up with based off others) , and no one was interested then it's a 20mil offer for part. If other firms are interested it's £80mil+, if a major rival is sniffing, £150-180mil+ plus part retention, if they feel a rival will bid, they'll re-visit alternatives, if they believe PYC to be better than all the rest, then you could be actually looking £500mil + you get a bidding war on that, who knows from there. That's how I see it.
Physiomics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
PYC
Physiomics
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200331 16:58:42